LIVE WEBINAR: Tuesday, August 8, 2023, 5:00 PM – 6:00 PM Eastern Time

Inside the Issue: Optimizing the Management of Metastatic Pancreatic Cancer

A CME/MOC-Accredited Live Webinar

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Tuesday, August 8th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Eileen M O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Co-Director, Medical Initiatives
David M Rubenstein Center for
Pancreatic Cancer Research
Chair
Human Research Protection Program and IRB
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck, and Novocure Inc.

Tuesday, August 8, 2023
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Selection and Sequencing of Therapy for Metastatic Pancreatic Cancer
  • Current and Future Role of Biomarker-Based Decision-Making for Metastatic Pancreatic Cancer

Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and colorectal surgeons, nurses and other allied healthcare professionals involved in the treatment of metastatic pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider relevant biological, clinical and logistical factors in the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD).
  • Appreciate recently published efficacy findings with nanoliposomal irinotecan as a component of first-line therapy for metastatic PAD, and assess the potential role of this novel therapeutic strategy.
  • Develop an evidence-based strategy for the treatment of metastatic PAD in patients who experience disease progression on front-line chemotherapy, exploring the importance of age, performance status and prior therapeutic exposure.
  • Appraise available Phase III data leading to the FDA approval of olaparib maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings for clinical practice.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD to support quality of life and continuation of therapy.
  • Recall the biologic rationale for and available and emerging data with other investigational agents currently in clinical testing for PAD, and refer eligible patients for trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr O'Reilly  — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Autem Therapeutics, Berry Genomics, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, FibroGen Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Neogene Therapeutics, Novartis, Servier Pharmaceuticals LLC, Tempus, Thetis Pharmaceuticals, Vector Pharma, Yiviva; Contracted Research: Agenus Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Puma Biotechnology Inc, QED Therapeutics, Yiviva; Nonrelevant Financial Relationship: Parker Institute for Cancer Immunotherapy. Dr WainbergAdvisory Committee and Consulting Agreements: Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Arcus Biosciences, Bristol Myers Squibb; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Pfizer Inc.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

SURVEY PARTICPANTS Tanios Bekaii-Saab, MD — Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KgaA, Merus BV, Pfizer Inc, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Caladrius Biosciences, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sanofi, Sobi, Stemline Therapeutics Inc, Treos Bio Ltd, Zai Lab; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Board: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Panbela Therapeutics Inc, Replimune, Xilis; Nonrelevant Financial Relationship: MJH Life Sciences, Pancreatic Cancer Action Network, UpToDate, The Valley Hospital. Kristen K Ciombor, MD, MSCI Advisory Committee: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis, Pfizer Inc, Replimune, Seagen Inc; Consulting Agreements: Merck, Pfizer Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc. Wells A Messersmith, MD — Consulting Agreements: Cardiff Oncology, Istari Oncology; Contracted Research: ALX Oncology, AStar EDDC, BeiGene Ltd, CanBas Co Ltd, Exelixis Inc, Fate Therapeutics, Pfizer Inc, PureTech Health, Mirati Therapeutics Inc, Rascal Therapeutics; Data and Safety Monitoring Board/Committee: Amgen Inc, QED Therapeutics, Zymeworks Inc; Unpaid Advisory Board: Pfizer Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Criterium. Philip A Philip, MD, PhD, FRCP — Advisory Committee: Bayer HealthCare Pharmaceuticals, Ipsen Biopharmaceuticals Inc, Merus BV, Novocure Inc, Pfizer Inc, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements: BioNTech SE, Totus Medicines; Contracted Research: Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Cyclacel Pharmaceuticals Inc, Oncolytics Biotech Inc; Speakers Bureau: Incyte Corporation, Servier Pharmaceuticals LLC. Michael Pishvaian, MD, PhDAdvisory Committee: Astellas, TriSalus Life Sciences; Consulting Agreements: AstraZeneca Pharmaceuticals LP, IDEAYA Biosciences, Merck, Merus BV, Novartis, Pfizer Inc, Seagen Inc; Contracted Research: Amgen Inc, Arcus Biosciences, Astellas, BioMed Valley Discoveries, Boehringer Ingelheim Pharmaceuticals Inc, Hutchison MediPharma, IDEAYA Biosciences, Merck, Novartis, Pfizer Inc, RenovoRx, Repare Therapeutics, Seagen Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc; Nonrelevant Financial Relationship: Perthera (stock ownership).

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck, and Novocure Inc.